Business
Jazz to Buy Actio Biosciences for $820M, Betting on a Rare Genetic Epilepsy
The deal adds ABS-1230, an oral drug for KCNT1-related epilepsy that has no approved treatment — Jazz’s second epilepsy acquisition in a year.